Source: GlobeNewswire

Press Release: Zosano Pharma : Zosano Announces Full Exercise of Underwriter's Option to Purchase Additional Shares

FREMONT, Calif., May 09, 2019 (GLOBE NEWSWIRE) -- Zosano Pharma Corporation (Nasdaq:ZSAN), a clinical-stage biopharmaceutical company, today announced that it has issued and sold an additional 750,000 shares of common stock, pursuant to the exercise in full of the underwriter's option to purchase additional shares in connection with Zosano's previously announced public offering of common stock. A total of 5,750,000 shares of common stock have now been sold by Zosano in the offering, resulting in net proceeds to Zosano of approximately $18.4 million, after deducting underwriting discounts and commissions and estimated offering expenses payable by Zosano.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Steven Lo's photo - President & CEO of Zosano Pharma

President & CEO

Steven Lo

CEO Approval Rating


Zosano Pharma is a clinical-stage biopharmaceutical company that researches, develops and commercializes novel therapeutics to treat migraines. Read more